N/A
Manufactured by Aurobindo Pharma Limited
5,260 FDA adverse event reports analyzed
Last updated: 2026-04-15
CEVIMELINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for CEVIMELINE HYDROCHLORIDE include DRUG INEFFECTIVE, HEADACHE, NAUSEA, DIARRHOEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CEVIMELINE HYDROCHLORIDE.
Out of 2,581 classified reports for CEVIMELINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 5,260 FDA FAERS reports that mention CEVIMELINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HEADACHE, NAUSEA, DIARRHOEA, FATIGUE, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with CEVIMELINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.